Tejas Patil, MD
Hospitalist · Aurora, CONPI 1336482769
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $80,317 of the $93,946 with a category attached, or 85.5%. It is spread thinly across 26 manufacturers, the largest accounting for just 16.7%. 2025 is the largest year on record at $29,556, more than ten times the $343 reported in 2019. Among hospitalist clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 100 payments — averaging $939.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$16K
- Takeda Pharmaceuticals U.S.A., Inc.$9K
- Gilead$9K
- E.r. Squibb & Sons, L.L.C.$8K
- Beigene Switzerland GmbH$8K
- Partner Therapeutics, Inc.$7K
- plus $38K from 20 others
Across 101 payments — averaging $13,909 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$497K
- Genentech, Inc.$346K
- Gilead$180K
- AstraZeneca$148K
- Takeda Pharmaceuticals U.S.A., Inc.$112K
- Pfizer$70K
- plus $53K from 2 others
What the payments were for
- Consulting fees$80,31785%
- Speaking & faculty fees$8,99810%
- Travel & lodging$2,0692%
- Food & beverage$2,4013%
- Education$1620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 18 | $15,721 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $9,206 |
| Gilead | 5 | $8,781 |
| E.r. Squibb & Sons, L.L.C. | 6 | $8,204 |
| Beigene Switzerland GmbH | 2 | $7,500 |
| Partner Therapeutics, Inc. | 14 | $6,787 |
| Pfizer | 4 | $5,516 |
| Regeneron | 4 | $4,832 |
| Janssen Scientific Affairs, LLC | 7 | $4,525 |
| Eli Lilly | 3 | $4,438 |
| Johnson & Johnson | 7 | $4,062 |
| Jazz Pharmaceuticals Inc. | 2 | $2,518 |
| Regeneron Healthcare Solutions, Inc. | 2 | $2,416 |
| EMD Serono, Inc. | 1 | $2,115 |
| Boehringer Ingelheim International GmbH | 1 | $1,950 |
| Janssen Global Services, LLC | 3 | $1,854 |
| Daiichi Sankyo Inc. | 1 | $1,250 |
| Boehringer Ingelheim | 2 | $868 |
| Aadi Bioscience, Inc. | 1 | $685 |
| Novocure GmbH | 1 | $250 |
| Genentech USA, Inc. | 2 | $162 |
| Spectrum Pharmaceuticals Inc. | 1 | $97 |
| Genentech, Inc. | 1 | $76 |
| Foundation Medicine, Inc. | 1 | $68 |
| Sanofi | 1 | $45 |
| Amgen | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$93,946 in reported general payments places this provider in the 95th percentile of 547 hospitalist providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 76 | $1,133,050 |
| AlecensaAlectinib Hcl | 29 | $498,755 |
| RetevmoSelpercatinib | 19 | $355,247 |
| LorbrenaLorlatinib | 12 | $251,352 |
| LumakrasSotorasib | 11 | $233,446 |
| EliquisApixaban | 33 | $40,321 |
| XareltoRivaroxaban | 21 | $23,403 |
| Levetiracetam | 14 | $716 |
| Oxycodone Hcl | 31 | $689 |
| Prochlorperazine Maleate | 46 | $574 |
| Morphine Sulfate ErMorphine Sulfate | 13 | $461 |
| Dexamethasone | 46 | $363 |
| Ondansetron Hcl | 44 | $310 |
| Trazodone Hcl | 14 | $132 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 11 | $131 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $15,721 | $1,133,05076 claims |
| Genentech USA, Inc.Alecensa | $162 | $498,75529 claims |
| PfizerLorbrena, Eliquis | $5,516 | $291,67345 claims |
| AmgenLumakras | $20 | $233,44611 claims |
| Johnson & JohnsonXarelto | $4,062 | $23,40321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 547 hospitalist providers in Colorado.
Other hospitalist in Aurora
- Michael SolaAurora$11K
- Susan CalcaterraAurora$6K
- Jeannette GuerrasioAurora$5K
- Mark BrittanAurora$4K
- Lilia CervantesAurora$3K
- Erin GordonAurora$3K
- Hemali PatelAurora$2K
- Alexander SunAurora$1K
- Benjamin WalkerAurora$1K
- David KlimplAurora$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.